SURF-201, a novel preservative-free topical formulation of betamethasone sodium phosphate, showed efficacy in preventing inflammation and pain in a post-cataract population.
In these eye drops, betamethasone sodium phosphate is present in a higher 0.2% concentration than in other formulations, allowing for reduced frequency of dosing, twice per day. The vehicle used contains chondroitin sulfate and was previously demonstrated to have beneficial properties on cell membrane stabilization and reduction of corneal edema.
In the phase 2 study, 83 subjects were randomly assigned 1:1 to receive